Should security be ordered?
10 The proceeding is a commercial dispute between corporations. Flujo alleges that it owned trade marks and intellectual property material to this proceeding from 2009 until March 2017 and, during this period, authorised Natvia Pty Ltd to use the trade marks and intellectual property. It is alleged that Natvia Pty Ltd has been carrying on a business of manufacturing, marketing, distributing and selling a natural stevia-based range of sweetener products under and by reference to the NATVIA name, trade mark and getup in Australia.
11 Although not pleaded, evidence before the Court establishes that Natvia Pty Ltd is a subsidiary of the fourth respondent, Flujo Sanguineo. Flujo and Flujo Sanguineo have common shareholders and directors, being Mark Anthony Hanna and Samuel Ben Kee Tew. As such, Flujo and Flujo Sanguineo are not related companies within the meaning of the Corporations Act 2001 (Cth) (companies are related if they have the same holding company, not if they have common individual shareholders).
12 In broad terms, Flujo alleges that the Merisant respondents carry on the business of manufacturing, marketing and selling sweetener products in Australia using brands and packaging that is deceptively similar to the brands and packaging used by Natvia Pty Ltd in the sale of its products. As noted earlier, Flujo alleges contraventions of the Australian Consumer Law and the Trade Marks Act 1995 (Cth) and seeks various forms of relief, including injunctions and damages or an account of profits. It is too early to make any assessment of the prospects of success of the claims.
13 The evidence adduced by the Merisant respondents concerning the financial position of Flujo establishes that Flujo is an Australian incorporated company with issued share capital of $2. It does not own any real property in Australia. There is no evidence that Flujo has any money in any bank account. Flujo owns two trade marks (not the trade marks in issue) and no other intellectual property. There is no evidence as to the financial value, if any, of the two trade marks owned by Flujo. Although Flujo previously owned the trade marks in issue in the proceeding, they were assigned to Flujo Sanguineo in March 2017 for no consideration. Flujo's assets are subject to the following security interests in favour of other entities:
(a) since 27 January 2012, Oxford Funding Pty Ltd has had a fixed and floating charge over "[a]ll present and future property and assets held by the corporation and the whole of the corporation's undertaking", with a maximum prospective liability of $10 million; and
(b) on 27 November 2017, Flujo granted a security interest in "[a]ll present and after-acquired property - no exceptions" to each of two other entities: Flujo Pty Ltd and Natvia Pty Ltd.
14 Flujo owns all of the shares in Natural Sweetener Co Pty Ltd and Norbu Sweetener Pty Ltd and 75% of the shares in Vitarium Holdings Pty Ltd. There is no evidence establishing the value of any of those shareholdings, and the evidence suggests that Natural Sweetener Pty Ltd and Norbu Sweetener Pty Ltd have no value. Natural Sweetener Co Pty Ltd has been under external administration following an action brought by the Commissioner of Taxation, and a liquidator was appointed in August 2016. The company has admitted debts in excess of $630,000 (including approximately $100,000 owed to Flujo). Norbu Sweetener Pty Ltd has also been under external administration following an action brought by the Commissioner of Taxation, and a liquidator was appointed in October 2016. The company has admitted debts in excess of $320,000. Vitarium Holdings Pty Ltd was under administration between June and December 2017 and there is no other evidence as to the value of its shares.
15 Mr Hanna's affidavit states that he and his business partner, Mr Tew, are ultimately responsible for the conduct of the various businesses owned by what he calls the Flujo Group (comprising Flujo, Flujo Sanguineo and their subsidiaries). As noted above, Flujo and Flujo Sanguineo are not related companies within the meaning of the Corporations Act 2001 (Cth), and the use of the description "Flujo Group" is apt to mislead. Mr Hanna states that the "Flujo Group" is an Australian SME (which I take to mean small to medium enterprise) with a successful range of sweetener and related products. However, Mr Hanna provided no information as to which companies conduct that business or the financial position of any such companies. No financial statements of any company are exhibited to his affidavit.
16 Mr Hanna further states that "Flujo and its related entities, including Flujo Sanguineo, are able to meet any costs ordered against it in this proceeding, collectively or individually". Again, I observe that Mr Hanna is in error in referring to Flujo Sanguineo as a related entity to Flujo. The only evidence adduced by Mr Hanna in support of that statement is a copy of a recent bank statement of Flujo Sanguineo. The bank statement is said to be confidential but I consider that there is no basis for a confidentiality order to be made. No submissions were made as to the reasons for the Court to make any confidentiality order in respect of the exhibit and I decline to do so. The bank statement is in respect of the period 31 January to 28 February 2019. It shows an opening balance as at 31 January 2019 of approximately $320,000 and then four transactions: a debit for the monthly plan fee, a debit which is designated "PYMT Natvia Pty Sanguineo Loan", a credit for interest paid and a debit which is designated "Payment by authority to Principal Finance". The closing balance is approximately $310,000. The affidavit does not explain those transactions or provide any evidence as to the purpose of the bank account. In my view, the bank statement of Flujo Sanguineo provides no evidence that Flujo would be able to meet an adverse costs order. As already noted, while Flujo and Flujo Sanguineo have common shareholders (Messrs Hanna and Tew), they are not related companies and, as far as the evidence discloses, Flujo Sanguineo has no obligation to meet debts incurred by Flujo.
17 Mr Hanna's affidavit also states that Flujo Sanguineo is willing to provide an undertaking to the Court to pay the costs of the Merisant respondents in this proceeding in the event they succeed. Apart from the bank statement referred to in the preceding paragraph, there is no evidence as to the ability of Flujo Sanguineo to satisfy such an undertaking. The bank statement does not provide a complete picture of the financial position of Flujo Sanguineo and there can be no assurance that the funds standing to the credit of the account as at the date of the bank statement are still in the account or will in the future remain in the account.
18 Doubt as to the ability of Flujo to meet an adverse costs order in the proceeding is heightened by the failure of Flujo to meet an adverse costs order that was made in parallel proceedings that were brought in the New Zealand High Court. Ms Smith gave evidence that Flujo initiated proceedings against the Merisant respondents and another company in the New Zealand High Court on 17 May 2016. Flujo sought but failed to obtain an interlocutory injunction in that proceeding. The allegations made by Flujo in the New Zealand proceeding were similar in nature to those made in this proceeding. The trial in the New Zealand proceeding was due to commence on 1 May 2017. However, on the last working day before the trial was due to commence, Flujo discontinued the New Zealand proceeding. The discontinuance appears to have been caused by Flujo's solicitors and counsel withdrawing from the case due to a disagreement over unpaid counsel's fees. On 18 July 2017, the New Zealand High Court made costs orders against Flujo in respect of the discontinued New Zealand proceeding. An appeal against those orders by Flujo was subsequently dismissed. In an affidavit dated 6 September 2017 filed in the New Zealand proceeding, Mr Hanna stated that Flujo intended to pay the costs award made against it due to discontinuance of the proceeding once the costs issue was resolved and the award of costs sealed. On 23 August 2018, the New Zealand High Court issued a Certificate of Judgment ordering that Flujo pay the Merisant respondents and another party the sum of $NZ103,978.25. On 26 October 2018, the Merisant respondents obtained from the Supreme Court of Victoria registration of the New Zealand costs order under the Trans-Tasman Proceedings Act 2010 (Cth) in the amount of NZ$103,978.25 plus interest of NZ$5,312.86 and costs of A$1,028. The Merisant respondents have sought payment of that amount from Flujo, but no payment has been made.
19 Ms Smith also gave evidence that, following the discontinuance of the New Zealand proceeding, on 9 June 2017 Flujo Sanguineo filed proceedings in the New Zealand High Court of against two of the Merisant respondents and two other companies. The allegations made in that proceeding are similar to those made in the discontinued proceeding in New Zealand.
20 Mr Hanna, as a director and shareholder of Flujo (and Flujo Sanguineo), was in a position to adduce evidence demonstrating that one or both of those companies had available assets to meet an adverse costs order in the proceeding. He failed to adduce such evidence. Mr Hanna was also in a position to explain the failure of Flujo to pay the New Zealand costs order, but his affidavit did not refer to that outstanding costs order.
21 Having regard to the evidence adduced by the Merisant respondents, in my view there is reason to believe that Flujo does not have available assets from which to meet an adverse costs order in this proceeding. An undertaking from Flujo Sanguineo to meet an adverse costs order does not provide adequate security for the Merisant respondents in circumstances where there is no evidence that Flujo Sanguineo is likely to have available assets from which to meet an adverse costs order in the future. I will therefore order Flujo to give security for the payment of costs that may be awarded against it.